Silence Therapeutics Plc (SLN) ADR EACH REPR 3 ORD SHS SPON

Sell:$4.90Buy:$4.97$0.18 (3.53%)

Prices delayed by at least 15 minutes
Sell:$4.90
Buy:$4.97
Change:$0.18 (3.53%)
Deal now
Prices delayed by at least 15 minutes
Sell:$4.90
Buy:$4.97
Change:$0.18 (3.53%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Key people

Craig A. Tooman
President, Chief Executive Officer, Executive Director
Rhonda Heliums
Chief Financial Officer, Executive Vice President
Steven J. Romano
Executive Vice President, Chief of Research and Development Officer
Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Timothy Mcinerney
Independent Director
David Jakob Lemus
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    SLN
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US82686Q1013
  • Market cap
    $243.73m
  • Employees
    116
  • Shares in issue
    141.64m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.